Skip to main content
GoodRx Care Direct

Get Zepbound® vials online

As low as $299 for medication
As low as $299 for medication
Delivery or pickup options
Delivery or pickup options
Only FDA-approved medications
Only FDA-approved medications
decorative accent in shape of sunbeams

As low as

$

299

per month

2

Zepbound® vials

tirzepatide
  • Self-injected GLP-1 medication for weight loss
  • Average weight loss of about 20% of initial body weight
  • Lowest dose $299/mo., higher doses $399/mo. or $449/mo.

GoodRx is NOT health insurance.

Cancel anytime.

Zepbound (tirzepatide) is a prescription GLP-1 and GIP medication used for weight loss and long-term weight management. It is also approved to treat moderate-to-severe obstructive sleep apnea in adults who are considered obese. It helps regulate appetite, leading to reduced calorie intake and weight loss.

Learn more about Zepbound

Zepbound (tirzepatide) works by mimicking two natural hormones, GLP-1 and GIP, which help regulate appetite, blood sugar, and digestion. By slowing how quickly food leaves the stomach and signaling the brain to reduce hunger, Zepbound helps lower calorie intake. Over time, these effects support steady weight loss and can also improve metabolic health.

Learn more about how Zepbound works

During clinical trials, people taking Zepbound (tirzepatide) started noticing weight loss about 4 weeks after starting it. This is how long it takes the medication to reach consistent levels in your body. Zepbound’s clinical trial ran for 72 weeks (about 16.5 months). People continued to lose weight throughout the study, but the greatest results were seen during the first 8 to 9 months of using Zepbound.

Learn more about how quickly Zepbound works

Some health insurance plans cover Zepbound (tirzepatide), and the landscape for GLP-1 coverage is rapidly changing. If you have insurance, review your plan’s summary of benefits and coverage and formulary (list of covered medications) to determine whether Zepbound is covered. If not, GoodRx Care Direct membership offers access to Zepbound vials starting at $299 a month for the lowest dose (plus $39 a month for unlimited online support from licensed healthcare providers).

Learn more about Zepbound insurance coverage

Through GoodRx Care Direct, qualified patients can get Zepbound (tirzepatide) vials starting at $299 a month for the lowest dose, plus necessary telehealth care and check-ins for $39 a month. Subsequent doses are $399 or $449 a month.

See if you’re eligible for Zepbound vials

Zepbound (tirzepatide) is considered safe for many people. It can cause side effects such as nausea, vomiting, diarrhea, and stomach pain, which usually improve over time. But Zepbound has also been linked to more serious side effects, such as pancreatitis, gallbladder disease, and gastroparesis. Your health history and other factors can help your healthcare provider determine if Zepbound is a good fit for you.

Learn more about Zepbound safety

See which weight loss treatment is right for you

Get started now

Other FAQs about Zepbound vials

Treatment with Zepbound (tirzepatide) starts with a low dose that gradually increases. The highest maintenance doses—10 mg or 15 mg once weekly—have shown the most significant weight loss results in clinical trials. However, the most effective dose varies by individual and depends on tolerability, side effects, and guidance from your healthcare provider.

Learn more about Zepbound dosage

Zepbound (tirzepatide) in vials is injected under the skin once weekly using a syringe. To prepare, draw the prescribed dose into the syringe, clean the injection site, and inject into the fatty tissue of the abdomen, thigh, or upper arm. Follow the detailed instructions that come with Zepbound vials.

Learn more about how to inject Zepbound

Zepbound (tirzepatide) in vials should be injected subcutaneously (right into the layer of fat under the skin) into the abdomen, thigh, or upper arm. Rotate injection sites each week to help prevent irritation or skin reactions. Injections should never be given into a vein or muscle. Follow the detailed instructions that come with Zepbound vials.

Learn more about where to inject tirzepatide

Both semaglutide (Wegovy) and tirzepatide (Zepbound) are effective GLP-1-based medications for weight management. Head-to-head studies comparing both medications show greater weight loss with Zepbound over Wegovy. This may be due to its dual action on GLP-1 and GIP receptors. However, results vary by individual, and side effects, cost, and insurance coverage are also important considerations.

Learn more about semaglutide and tirzepatide

Yes, Zepbound (tirzepatide) needs to be refrigerated. Zepbound should be stored in the refrigerator between 36°F and 46°F (2°C to 8°C). If needed, it can be kept at room temperature—up to 86°F (30°C)—for up to 21 days. Always keep it in its original packaging to protect it from light and never freeze it.

Learn more about storing Zepbound

Zepbound (tirzepatide) in both vials and pens is manufactured by Eli Lilly and Company, an American pharmaceutical company founded in 1876.

There are a number of options for getting Zepbound (tirzepatide) vials online. GoodRx Care Direct offers unlimited access to licensed healthcare professionals who can write a prescription for Zepbound for weight loss if it is a good fit for you, plus provide ongoing support to help you reach the most effective dose.

See if you’re eligible for Zepbound

Real treatment. Real results.

Get care from licensed healthcare providers as you work up to your most effective GLP-1 dose.

$39 /month

for unlimited online care

As low as

$299 /month*

for Zepbound (tirzepatide) vials

Get started

See what’s possible with GLP-1s

Find out how much you could lose with brand-name medications.
Get started

** Results from this calculator are for illustrative purposes only and are not a guarantee or prediction of individual results. This calculation applies a universal 20% weight loss factor. A 72-week study of adults without diabetes and a BMI of 30 or greater, or a BMI of 27 or greater with a weight-related condition, lost on average 20% with tirzepatide and 14% with semaglutide.